Bragar Eagel Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Abbott, TuSimple, Humanigen, and Kohl''s and Encourages Investors to Contact the Firm NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Abbott Laboratories (NYSE: ABT ), TuSimple Holdings, Inc. (NASDAQ: TSP ), Humanigen, Inc. (NASDAQ: HGEN ), and Kohl''s Corporation (NYSE: KSS ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Abbott Laboratories (NYSE: ABT ) Class Period: February 19, 2021 – June 8, 2022 Lead Plaintiff Deadline: October 31, 2022 Abbott manufactures various forms of infant formula including formula sold under the brand names Similac, Alimentum, and EleCare. Prior to February 2022, Abbott had produced 40% of the United States'' infant formula. Of that amount, nearly half was produced in its manufacturing facility in Sturgis, MI. On February 17, 2022, the US Food and Drug Administration ("FDA") announced it was investigating four consumer complaints of infant illness related to powdered infant formula produced by Abbott Laboratories in Sturgis.